ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genetic Targeting
ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genetic Targeting
ARCA biopharma, Inc. , a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.